Infliximab (Remicade®, Inflectra®, Renflexis®, Avsola™)

Infliximab (Remicade, Inflectra, Renflexis, Avsola) is covered for FDA‑approved and specified off‑label compendial indications (e.g., Crohn’s, ulcerative colitis, RA, psoriasis, ankylosing spondylitis, Behçet’s, GVHD, hidradenitis suppurativa, JIA, uveitis, etc.) and excluded for non‑compendial uses; coverage requires indication‑specific prior therapy trials or documented contraindications, prescription/consultation by the required specialist, applicable age limits (e.g., ≥6 for IBD, ≥18 for plaque psoriasis), objective diagnostic documentation, adherence to specified dosing/infusion schedules and maximums, and documented clinical response for reauthorization.

"Crohn's disease"

Sign up to see full coverage criteria, indications, and limitations.